The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Two recent tools in the battle for weight loss have been showing incredible results: Semaglutide and Tirzepatide. Stephanie Davison from Skin Envy Non-Surgical Weight Loss Center, and Registered ...

[vi] In light of the OFA’s lawsuit, the FDA issued clarifying guidance on when compounders must cease compounding semaglutide. For compounders that have relied on the drug shortage to compound ...

Researchers discovered semaglutide—the active ingredient in Ozempic and Wegovy—may reduce the risk of death and lower the chance of developing cardiovascular conditions like stroke and heart ...

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...